Based on these three receptors, Luminal A/B (ER+), HER2+, and triple-negative breast cancers (TNBC, ER-/PR-/HER2-) are identified [2] with different molecular profiles, clinical outcomes, and treatment responses [3]. Here, ESR1 is linked to triple-negative breast carcinoma.